News & Updates

Show Multimedia Only
Cardiometabolic risk tied to NAFLD

Cardiometabolic risk tied to NAFLD

16 Apr 2022

Cardiometabolic risk factors increase the risk of nonalcoholic fatty liver disease (NAFLD), though such interactions seem to vary between lean and nonlean individuals, a recent study has found.

16 Apr 2022
Seladelpar safe, effective for primary biliary cholangitis

Seladelpar safe, effective for primary biliary cholangitis

10 Apr 2022

In patients with primary biliary cholangitis, the use of seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, safely improves biochemical markers of cholestasis and inflammation, reports a new study.

10 Apr 2022
Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma

Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma

08 Mar 2022 byJairia Dela Cruz

Among advanced hepatocellular carcinoma patients being treated with immune checkpoint inhibitors (ICIs), the occurrence of multisystem and more severe immune-related adverse events is a favourable signal, being associated with survival advantage, according to a Singapore study.

08 Mar 2022